Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland
Open accessThe DOI matches its Crossref record; 35 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the contemporaneous prevalence of diabetic peripheral neuropathy (DPN) in people with type 1 diabetes (T1D) in Scotland and study its cross-sectional association with risk factors and other diabetic complications. RESEARCH DESIGN AND METHODS: We analyzed data from a large representative sample of adults with T1D (N = 5,558). We assessed the presence of symptomatic neuropathy using the dichotomized (≥4) Michigan Neuropathy Screening Instrument Patient Questionnaire score. Logistic regression models were used to investigate associations between DPN and risk factors, as well as with other complications. RESULTS: The burden of DPN is substantial with 13% prevalence overall. Adjusting for attained age, diabetes duration, and sex, the odds of DPN increased mainly with waist-to-hip ratio, lipids, poor glycemic control (odds ratio 1.51 [95% CI 1.21–1.89] for levels of 75 vs. 53 mmol/mol), ever versus never smoking (1.67 [1.37–2.03]), and worse renal function (1.96 [1.03–3.74] for estimated glomerular filtration rate levels <30 vs. ≥90 mL/min/1.73 m2). The odds significantly decreased with higher HDL cholesterol (0.77 [0.66–0.89] per mmol/L). Living in more deprived areas was associated with DPN (2.17 [1.78–2.65]) for more versus less deprived areas adjusted for other risk factors. Finally, individuals with prevalent DPN were much more likely than others to have other diabetes complications. CONCLUSIONS: Diabetic neuropathy remains substantial, particularly affecting those in the most socioeconomically deprived groups. Those with clinically manifest neuropathy also have a higher burden of other complications and elevated levels of modifiable risk factors. These data suggest that there is considerable scope to reduce neuropathy rates and narrow the socioeconomic differential by better risk factor control.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603 · cited 1×
“73m2) were computed using the CKD Epidemiology Collaboration formula eGFR (24).”
MethodMultimodel Inference: Understanding AIC and BIC in Model Selection
Burnham, K. P., & Anderson, D. R. (2004) · Sociological Methods & Research · doi:10.1177/0049124104268644 · Cited by 11,648
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
Vascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293
Diabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211 · cited 1×
“Drug treatment of DPN mainly comprises symptom control using anticonvulsants and antidepressants (7,12, 13), with duloxetine and pregabalin being among the first-line therapies indicated in the major guidelines (14).”
BackgroundTesfaye, S., Stevens, L. K., Stephenson, J. M., Fuller, J. H., Plater, M., Ionescu-Tirgoviste, C., Nuber, A., Pozza, G., & Ward, J. D. (1996) · Diabetologia · doi:10.1007/s001250050586 · Cited by 695 · cited 4×
“The data reinforce previous findings (26) and give support to the idea of a holistic, comprehensive approach to diabetes management.”
BackgroundResultInfluential
Research works printed but not linked: 1
- Scottish Intercollegiate Guidelines Network, 2010, Management of Diabetes: A National Clinical Guideline
Cited by
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Elafros, M. A., Andersen, H., Bennett, D. L., Savelieff, M. G., Viswanathan, V., Callaghan, B. C., & Feldman, E. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00188-0 · Cited by 387
Diabetic neuropathy: cutting-edge research and future directions
Yang, Y., Zhao, B., Wang, Y., Lan, H., Liu, X., Hu, Y., & Cao, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02175-1 · Cited by 234
“For example, when using questionnaires like MNSIQ, the prevalence of DN in T1DM patients is estimated at 11 – 13%; 29,30 however, when structured clinical examinations and vibration perception thresholds are used, the prevalence increases to 28%.”
Tobias, D. K., Merino, J., Ahmad, A., Aiken, C., Benham, J. L., Bodhini, D., Clark, A. L., Colclough, K., Corcoy, R., Cromer, S. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02502-5 · Cited by 217
Metadata
- Authors
- Jeyam, A., McGurnaghan, S. J., Blackbourn, L. A. K., McKnight, J. M., Green, F., Collier, A., McKeigue, P. M., & Colhoun, H. M.
- Affiliations
- Institute of Genetics and Cancer (GB)
- NHS Lothian (GB)
- Dumfries and Galloway Royal Infirmary (GB)
- University Hospital Ayr (GB)
- University of Edinburgh (GB)
- National Health Service (GB)
- Corresponding author
- Jeyam, Anita
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-01-23
- Volume
- 43
- Issue
- 4
- Pages
- 734-742
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3002419256
- Semantic Scholar
- 797905057922d7edb07aa82ecfc9c634ef3b3724
- Cited by
- 59
- References
- 38
- Citations by year
- 2026: 5 · 2025: 19 · 2024: 16 · 2023: 6 · 2022: 8 · 2021: 3 · 2020: 2
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (acceptedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- Chief Scientist Office (ETM/47)
- Diabetes UK (10/0004010)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Keywords
- diabetic peripheral neuropathy, type 1 diabetes, socioeconomic deprivation, prevalence, risk factors, glycemic control, renal function, smoking, waist-to-hip ratio, lipids, HDL cholesterol, diabetes complications, Michigan Neuropathy Screening Instrument, Scotland
- MeSH terms
- Adolescent, Adult, Cross-Sectional Studies, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Female, Humans, Male, Middle Aged, Risk Factors, Scotland, Socioeconomic Factors, Prevalence, Vulnerable Populations, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland. https://app.cochat.ai/papers/10.2337/dc19-1582
- The paper
- Jeyam, A., McGurnaghan, S. J., Blackbourn, L. A. K., McKnight, J. M., Green, F., Collier, A., McKeigue, P. M., & Colhoun, H. M. (2020). Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland. Diabetes Care. https://doi.org/10.2337/dc19-1582
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.